Agios Pharmaceuticals Inc (NASDAQ: AGIO) on Friday, plunged -3.66% from the previous trading day, before settling in for the closing price of $30.63. Within the past 52 weeks, AGIO’s price has moved between $19.80 and $35.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 2.66% over the past five years. The company achieved an average annual earnings per share of -5.34%. With a float of $54.74 million, this company’s outstanding shares have now reached $55.95 million.
Let’s look at the performance matrix of the company that is accounted for 383 employees.
Agios Pharmaceuticals Inc (AGIO) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Agios Pharmaceuticals Inc is 2.58%, while institutional ownership is 106.21%. The most recent insider transaction that took place on Apr 10 ’24, was worth 214,642. In this transaction Director of this company sold 7,791 shares at a rate of $27.55, taking the stock ownership to the 137,396 shares. Before that another transaction happened on Mar 07 ’24, when Company’s Director sold 1,285 for $31.62, making the entire transaction worth $40,632. This insider now owns 5,524 shares in total.
Agios Pharmaceuticals Inc (AGIO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 120.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.00% during the next five years compared to -0.98% drop over the previous five years of trading.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
Agios Pharmaceuticals Inc (AGIO) is currently performing well based on its current performance indicators. A quick ratio of 11.99 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 61.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.33, a number that is poised to hit -1.64 in the next quarter and is forecasted to reach -5.89 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Agios Pharmaceuticals Inc (NASDAQ: AGIO) saw its 5-day average volume 0.8 million, a negative change from its year-to-date volume of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 80.32%. Additionally, its Average True Range was 1.22.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 58.80%, which indicates a significant decrease from 61.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.48% in the past 14 days, which was lower than the 45.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.88, while its 200-day Moving Average is $25.43. Nevertheless, the first resistance level for the watch stands at $30.57 in the near term. At $31.62, the stock is likely to face the second major resistance level. The third major resistance level sits at $32.55. If the price goes on to break the first support level at $28.58, it is likely to go to the next support level at $27.65. The third support level lies at $26.60 if the price breaches the second support level.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
Market capitalization of the company is 1.66 billion based on 56,195K outstanding shares. Right now, sales total 26,820 K and income totals -352,090 K. The company made 7,100 K in profit during its latest quarter, and -95,940 K in sales during its previous quarter.
